Reducing the Risk of Relapse in Patients With Pancreatic Cancer

Publication
Article
Special ReportsGastrointestinal Cancers (Issue 1)
Volume 1
Issue 1

Robert L. Fine, MD, from Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.

Robert L. Fine, MD, associate professor of medicine, Herbert Irving, director, Experimental Therapeutics, medical oncology director, Pancreas Center, Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.

Read more abouta hedgehog pathway inhibitor for the treatment of advanced pancreatic cancer > >

Articles in this issue
The Identification of Molecular Subtypes of Gastric Cancer
The Identification of Molecular Subtypes of Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
Ramucirumab Combo Increases Survival in Gastric Cancer
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
<em>RAS</em> Status Matters in mCRC: Confirmed by Second-Line Data
New Standard of Neoadjuvant Care for Rectal Cancer Established
New Standard of Neoadjuvant Care for Rectal Cancer Established
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Reducing the Risk of Relapse in Patients With Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
Vismodegib Demonstrates Activity in Advanced Pancreatic Cancer
The Treatment of Advanced Colorectal Cancer
The Treatment of Advanced Colorectal Cancer
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
Studies Emphasize Need for Full <em>RAS</em> Mutational Analyses in the Management of mCRC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC
TTP, OS Benefit Seen Following Treatment With TGF-β Inhibitor in HCC

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Current Immunotherapy: Progress With Adoptive Cellular Therapies and Combinations
Current Immunotherapy: Progress With Adoptive Cellular Therapies and Combinations
Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC
Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Dr. Bazhenova on the Prevalence of Patients With Non-Driver NSCLC
Dr. Bazhenova on the Prevalence of Patients With Non-Driver NSCLC
Dr. Bazhenova on Current Treatment Strategies for Patients With Nonsquamous NSCLC
Dr. Bazhenova on Current Treatment Strategies for Patients With Nonsquamous NSCLC
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
Dr. Bazhenova on Remaining Challenges and Future Treatment Landscape of Non-Driver NSCLC
Dr. Bazhenova on Remaining Challenges and Future Treatment Landscape of Non-Driver NSCLC
Related Content
Targeting FRα and B7-H4 in Endometrial Cancer

Targeting FRα and B7-H4 in Endometrial Cancer

Jax DiEugenio
April 9th 2025
Article

A retrospective study showed that either folate receptor alpha or B7-H4 was expressed in more than 80% of endometrial cancers evaluated.

Read More

Americans’ Frustration With The Health Care Industry Builds

Americans’ Frustration With The Health Care Industry Builds

Lindsay Dymowski Constantino
April 8th 2025
Article

Read More

HIF-2α Inhibitors Make Significant Inroads in Renal Cell Carcinoma

HIF-2α Inhibitors Make Significant Inroads in Renal Cell Carcinoma

Tony Berberabe, MPH
April 7th 2025
Article

Read More

Insights from ASCO GI and the Future of CAR T-Cell Therapy in Solid Tumors

Insights from ASCO GI and the Future of CAR T-Cell Therapy in Solid Tumors

Robert L. Ferris, MD, PhD
April 4th 2025
Article

The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell therapies for solid tumors.

Read More

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond

Jonah Feldman
March 21st 2025
Article

Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.

Read More

Lee Evaluates Chronic GVHD Therapies for Depth and Durability of Response

Lee Evaluates Chronic GVHD Therapies for Depth and Durability of Response

Targeted Oncology Staff
March 20th 2025
Article

During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents for treating chronic graft-vs-host disease.

Read More